This initial price to me seems driven by the the desire by the Janssen Top brass to justify the cost of development and the promise that they thought would be there. I look for the price to quickly modulate downward if Sofosbuvir is anywhere close to it. The real world corporate thinking is start high and we can always lower the price, but they are playing a gamble being quite a bit higher that the current choices. Insurance company's may baulk as it's higher cost. Time will lower most Meds.
matt
Tig said
Nov 27, 2013
Appalled is putting it mildly! The greed of big pharm seems to get bigger with each and every successful trial. Certainly their disregard for the patient and their family grows unchecked. It's disgraceful...
mallani said
Nov 27, 2013
Hi Jill,
I am appalled! That's ~$800 per pill!
Victrelis costs $31k for 24 weeks, and $48K for 44 weeks. Incivek costs $49k for 12 weeks. Janssen/Medivir have just modified a predetermined antiprotease structure, and not very well. Where's the pan-genotype activity, the indepence of IL28B genotype, and why is it much poorer in F3 and F4? They must have some friends in the FDA, as the patients numbers in their Phase 3 Trials were very small( 394 in Quest 1, 391 in Quest 2, and 260 in Promise). How can they justify a price tag of $66k for such a very minor advance? Merck-5172 is a seriously more effective antiprotease.
I hope Olysio is ignored by the Medical Profession.
Zlikster said
Nov 27, 2013
"niiiice"
66k$ Simeprevir + 80k $ Sofosbuvir and few thousands for Riba...and voila! ;)
Cinnamon Girl said
Nov 27, 2013
(Well, we knew it wasn`t going to be cheap!)
`November 26 2013 - Janssen's hepatitis C drug Olysio (simeprevir) scored FDA approval Friday evening, kicking off a new wave of hepatitis C drugs. It offers modest benefit over standard of care, but a subgroup of patients has encountered resistance, and the med could have trouble catching on as newer antivirals become more broadly available for treating the liver-destroying disease.
An NS3/4A protease inhibitor, Olysio was approved as part of a treatment regimen that also includes pegylated interferon (INF) and ribavirin (RBV) in patients with genotype-1 infection, which accounts for most cases of the virus. It followed a unanimous vote from an FDA ad-com panel in October for that same genotype.
Janssen has priced Olysio at a wholesale acquisition price of $22,120 per bottle of 28 capsules (150 mg capsules), which is an approximately one-month supply. "We believe that the price of Olysio reflects its value and demonstrated efficacy and safety profile," said Janssen spokesman Craig Stoltz via e-mail, adding that Janssen is offering a support program including help with access. That's roughly $66,360 for a three-month course.`
Hey all
This initial price to me seems driven by the the desire by the Janssen Top brass to justify the cost of development and the promise that they thought would be there. I look for the price to quickly modulate downward if Sofosbuvir is anywhere close to it. The real world corporate thinking is start high and we can always lower the price, but they are playing a gamble being quite a bit higher that the current choices. Insurance company's may baulk as it's higher cost. Time will lower most Meds.
matt
Appalled is putting it mildly! The greed of big pharm seems to get bigger with each and every successful trial. Certainly their disregard for the patient and their family grows unchecked. It's disgraceful...
Hi Jill,
I am appalled! That's ~$800 per pill!
Victrelis costs $31k for 24 weeks, and $48K for 44 weeks. Incivek costs $49k for 12 weeks. Janssen/Medivir have just modified a predetermined antiprotease structure, and not very well. Where's the pan-genotype activity, the indepence of IL28B genotype, and why is it much poorer in F3 and F4? They must have some friends in the FDA, as the patients numbers in their Phase 3 Trials were very small( 394 in Quest 1, 391 in Quest 2, and 260 in Promise). How can they justify a price tag of $66k for such a very minor advance? Merck-5172 is a seriously more effective antiprotease.
I hope Olysio is ignored by the Medical Profession.
66k$ Simeprevir + 80k $ Sofosbuvir and few thousands for Riba...and voila! ;)
(Well, we knew it wasn`t going to be cheap!)
`November 26 2013 - Janssen's hepatitis C drug Olysio (simeprevir) scored FDA approval Friday evening, kicking off a new wave of hepatitis C drugs. It offers modest benefit over standard of care, but a subgroup of patients has encountered resistance, and the med could have trouble catching on as newer antivirals become more broadly available for treating the liver-destroying disease.
An NS3/4A protease inhibitor, Olysio was approved as part of a treatment regimen that also includes pegylated interferon (INF) and ribavirin (RBV) in patients with genotype-1 infection, which accounts for most cases of the virus. It followed a unanimous vote from an FDA ad-com panel in October for that same genotype.
Janssen has priced Olysio at a wholesale acquisition price of $22,120 per bottle of 28 capsules (150 mg capsules), which is an approximately one-month supply. "We believe that the price of Olysio reflects its value and demonstrated efficacy and safety profile," said Janssen spokesman Craig Stoltz via e-mail, adding that Janssen is offering a support program including help with access. That's roughly $66,360 for a three-month course.`
Full article...
http://hepatitiscnewdrugresearch.com/-olysiotrade-simeprevir-cost.html